James Maitland stands at the intersection of medical innovation and industrial strategy, bringing years of expertise in how technology and policy shape the future of healthcare. As global trade routes shift and manufacturing hubs relocate, his insights offer a crucial window into the survival of domestic medical device ecosystems. Today, we explore the intensifying pressure on local production as low-cost imports flood the market, threatening to undermine years of investment and the very foundation of self-reliant healthcare infrastructure.
The discussion delves into the alarming doubling of dialyser imports from specific regions and the broader 14% surge in medical goods entering through free trade agreements. We examine the sophisticated tactics used to bypass tariffs by routing Chinese goods through neighboring nations, the struggle for domestic firms to remain competitive in price-sensitive government tenders, and the critical need for a tariff structure that supports the manufacturing of high-tech components like X-ray tubes.
With dialyser imports from specific regions doubling to over Rs 250 crore recently, how has this influx impacted the morale and strategic planning of domestic manufacturers who have heavily invested in local infrastructure?
It is a deeply unsettling time for manufacturers who have poured their hearts, souls, and significant capital into building world-class facilities on home soil. When you look at the hard data showing dialyser imports from Malaysia and China doubling to Rs 256 crore in just the last two years, it sends a shiver through the entire boardrooms of these companies. Many of these players made these commitments under the government’s Production Linked Incentive (PLI) scheme, believing they were building a secure future for domestic healthcare. Now, they face an environment where artificially depressed prices are suffocating their ability to compete, leaving them to wonder if their significant investments in R&D and quality standards were made in vain. It’s hard to justify further expansion when the market you’re trying to serve is being saturated by products that don’t seem to play by the same economic rules.
The industry is raising alarms about Chinese-origin products entering the market through neighboring trade partners. Could you explain the mechanics of how these routed imports undermine local efforts?
What we are witnessing is a sophisticated game of “origin-hopping” that exploits the zero-duty benefits of free trade agreements to bypass protective measures. By routing Chinese-origin devices through ASEAN countries, exporters can take advantage of a zero-tariff regime that was originally intended to foster genuine regional partnership, not act as a backdoor for third-party dumping. This trend has led to a 14% surge in imports from the region, reaching nearly Rs 13,000 crore in the recent fiscal year, covering everything from syringes and medical gloves to complex imaging equipment. For a local manufacturer, this feels like fighting an invisible opponent; they are competing against zero-duty goods that are often priced below the cost of raw materials in a fair market. It creates a massive hurdle for recovering investment costs and undermines the entire medtech manufacturing base that we have worked so hard to establish.
In the context of government tenders, where the lowest price often wins, how are domestic producers of disposables and imaging equipment being pushed out of their own market?
The current procurement model, which almost exclusively rewards the lowest price or “L1” bidder, has become a major roadblock for domestic innovation and sustainability. In government tenders, where large-scale contracts are awarded, domestic manufacturers of disposables like surgical gloves and imaging equipment find themselves at a distinct disadvantage. They are burdened by the costs of high-quality local production, while low-priced imports—often benefiting from the zero-tariff loopholes I mentioned—can easily underbid them. This creates a scenario where the industry becomes uncompetitive in its own backyard, forced to watch as essential healthcare contracts are handed to foreign entities. If we continue to prioritize the immediate bottom line over the long-term health of our manufacturing sector, we risk losing the very factories that provide local jobs and ensure supply chain security during global crises.
Key components for high-tech imaging, such as X-ray tubes and flat-panel detectors, remain heavily import-dependent. What is the path forward for scaling indigenous production of these sophisticated parts?
Moving up the value chain to produce critical components like X-ray tubes and flat-panel detectors is the essential next step, but it requires a much more stable and protective environment than what we have now. At the moment, unchecked low-priced imports, particularly from China, make it incredibly difficult for domestic manufacturers to justify the massive scale of investment needed for indigenous production. We need to look closely at our tariff structures for these specific inputs to ensure they actually support the people trying to build them locally rather than inadvertently favoring the finished imported machine. It is a technical and financial challenge that requires a “brave” capital approach, where the government and industry work together to shield these infant high-tech niches until they reach a scale where they can stand on their own. Without this, we will continue to be a nation that merely assembles parts made elsewhere, rather than a true innovator in the imaging space.
As manufacturing bases shift to countries like Vietnam to avoid international tariffs, how should the domestic industry prepare for this new wave of global competition and “routed” goods?
We have to recognize that the global manufacturing map is being redrawn in real-time, and we are currently in a very vulnerable position. As factories shift to Vietnam to escape US tariff measures, there is a legitimate fear that these products will be redirected toward us, creating a new wave of routed imports that exploit existing trade loopholes. This makes the urgent renegotiation of free trade agreements not just a policy suggestion, but a matter of industrial survival to safeguard our domestic industry. We must tighten our “rules of origin” to ensure that only products with genuine regional value-add receive duty-free access, effectively closing the door on the practice of simply re-labeling foreign goods. If we don’t fortify our regulatory borders now, the progress we’ve made in medtech could be hollowed out before it even reaches its full potential.
What is your forecast for the medical device manufacturing sector?
I believe we are standing at a critical crossroads where the decisions made in the next eighteen months will determine the trajectory of the industry for the next two decades. If we can successfully implement anti-dumping measures and close the loopholes in our trade agreements, I forecast a robust resurgence where domestic manufacturing could eventually meet 70% of our internal demand, up from the current levels. However, if the surge in imports—which has already hit nearly Rs 13,000 crore—continues unchecked, we will likely see a stagnation where even the most innovative local companies are forced to pivot back to being mere distributors. The potential for India to be a global medtech hub is palpable, but it requires a level playing field where quality and local investment are valued at least as much as the lowest possible price point.
